Reviewing Allogene Therapeutics Alvotech
| CLLS Stock | USD 1.87 0.01 0.54% |
Slightly above 54% of Cellectis' investor base is interested to short. The analysis of the overall investor sentiment regarding Cellectis SA suggests that many traders are impartial. Cellectis' investing sentiment can be driven by a variety of factors including economic data, Cellectis' earnings reports, geopolitical events, and overall market trends.
Cellectis |
Alvotech and Allogene Therapeutics are both small-cap medical companies, but which is the better investment We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability. Analyst Ratings This is a breakdown of recent
Read at thelincolnianonline.com
 |
Cellectis Fundamental Analysis
We analyze Cellectis' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Cellectis is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Cellectis SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cellectis stock to make a market-neutral strategy. Peer analysis of Cellectis could also be used in its relative valuation, which is a method of valuing Cellectis by comparing valuation metrics with similar companies.
Peers
Cellectis Related Equities
| DMAC | DiaMedica Therapeutics | 12.44 | ||||
| HCWB | HCW Biologics | 8.45 | ||||
| SLNO | Soleno Therapeutics | 5.77 | ||||
| RGNX | Regenxbio | 4.47 | ||||
| KYMR | Kymera Therapeutics | 3.38 | ||||
| GLUE | Monte Rosa | 1.68 | ||||
| FHTX | Foghorn Therapeutics | 1.55 | ||||
| INBX | Inhibrx | 0.72 | ||||
| GNFT | Genfit | 0.94 | ||||
| STTK | Shattuck Labs | 0.99 | ||||
| NRIX | Nurix Therapeutics | 1.43 | ||||
| KZR | Kezar Life | 1.57 | ||||
| CRNX | Crinetics Pharmaceuticals | 1.70 | ||||
| ELYM | Eliem Therapeutics | 2.60 | ||||
| ANEB | Anebulo Pharmaceuticals | 2.67 | ||||
| IPHA | Innate Pharma | 4.12 | ||||
| PASG | Passage Bio | 5.56 |
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.